- Home
- SQNS vs CLYM Comparison
SQNS vs CLYM Comparison
Compare SQNS & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- CLYM
- Stock Information
- Founded
- SQNS 2003
- CLYM 2018
- Country
- SQNS France
- CLYM United States
- Employees
- SQNS N/A
- CLYM N/A
- Industry
- SQNS Semiconductors
- CLYM
- Sector
- SQNS Technology
- CLYM
- Exchange
- SQNS Nasdaq
- CLYM NYSE
- Market Cap
- SQNS 85.7M
- CLYM 101.6M
- IPO Year
- SQNS 2011
- CLYM 2021
- Fundamental
- Price
- SQNS $1.88
- CLYM $1.21
- Analyst Decision
- SQNS Strong Buy
- CLYM
- Analyst Count
- SQNS 1
- CLYM 0
- Target Price
- SQNS $7.50
- CLYM N/A
- AVG Volume (30 Days)
- SQNS 65.2K
- CLYM 197.4K
- Earning Date
- SQNS 02-11-2025
- CLYM 05-14-2025
- Dividend Yield
- SQNS N/A
- CLYM N/A
- EPS Growth
- SQNS N/A
- CLYM N/A
- EPS
- SQNS 2.00
- CLYM N/A
- Revenue
- SQNS $36,762,000.00
- CLYM N/A
- Revenue This Year
- SQNS N/A
- CLYM N/A
- Revenue Next Year
- SQNS $95.51
- CLYM N/A
- P/E Ratio
- SQNS $0.98
- CLYM N/A
- Revenue Growth
- SQNS 9.36
- CLYM N/A
- 52 Week Low
- SQNS $0.95
- CLYM $1.05
- 52 Week High
- SQNS $4.28
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- SQNS 27.16
- CLYM N/A
- Support Level
- SQNS $1.87
- CLYM N/A
- Resistance Level
- SQNS $2.18
- CLYM N/A
- Average True Range (ATR)
- SQNS 0.14
- CLYM 0.00
- MACD
- SQNS -0.01
- CLYM 0.00
- Stochastic Oscillator
- SQNS 6.45
- CLYM 0.00
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.